Market news

SOLV's strong Q2 performance, growth investments and cost-saving program support its outlook, though higher raw material costs remain a concern.

Earlier this quarter, Solventum reported results that surpassed analyst expectations, with both organic revenue and EPS beating estimates and management emphasizing strong execution and ongoing transformation efforts. An interesting angle is how Solventum’s exposure to surgical equipment and consumables, including AI and robotics-enabled solutions, supports relatively consistent procedural demand and innovation-driven opportunities. Now we’ll explore how this stronger-than-expected quarter,...

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q2. Today, we are looking at surgical equipment & consumables - diversified stocks, starting with Solventum (NYSE:SOLV).

Solventum's growth, higher earnings outlook and cost cuts strengthen its case, but heavy debt and 2027 margin risks temper the upside.

Solventum plans to spin off its $1.4B HIS business, sharpening its MedTech focus while giving HIS more flexibility to pursue growth.

Solventum has underperformed the broader market, while analysts remain moderately optimistic about its future prospects.

Healthcare solutions provider Solventum (NYSE:SOLV) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 2.2% year on year to $2.21 billion. Its non-GAAP profit of $2.55 per share was 33.8% above analysts’ consensus estimates.

Solventum shares gain on strong Q2 revenue, earnings, and cash flow, buybacks, and improved guidance, with analysts raising price targets amid a discounted valuation versus med/tech peers.

Solventum (SOLV) has an average rating of overweight and mean price target of $95, according to anal

The software business needs “a different investment level” to quickly realize its potential, Solventum’s CEO said.

Solventum (SOLV) delivered earnings and revenue surprises of +33.51% and +2.03%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

The headline numbers for Solventum (SOLV) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Healthcare solutions provider Solventum (NYSE:SOLV) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 2.2% year on year to $2.21 billion. Its non-GAAP profit of $2.55 per share was 33.8% above analysts’ consensus estimates.

Solventum (SOLV) reported Q2 adjusted diluted earnings late Wednesday of $2.55 per share, up from $1

Solventum (NYSE: SOLV) today reported financial results for the second quarter ended June 30, 2026.